A phase I dose escalation study of the combination of dasatinib (BMS-354825) and imatinib in subjects with chronic myeloid leukemia in chronic phase
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Dasatinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 08 Feb 2007 Status changed from in progress to withdrawn prior to recruitment.
- 02 Feb 2007 Status changed from recruiting to in progress.